No point to be a ramper on no information. I think that if you...

No point to be a ramper on no information. I think that if you look carefully at the accounts IMO the concerns expressed by some about funding are likely to be inaccurate, and the action will start end of the year. Still a bit disappointing about the FE loss, but it's not clear if the situation improved after the accounts were published or whether they just booked the loss and changed strategy.

No more point to me speculating until we get an update. However its clear they are putting everything in place to be prepared for a good trial result. If they are planning to combine OPT302 with a Lucentis the new COO has previous experience with Novartis. Possibly she still has management contacts there and she now has an active management role rather than just an advisory one.